Fecal Microbiota(University Hospital Heidelberg)

The interventional, randomized, placebo-controlled, single blind phase II-trial FLORA will assess safety and immunogenicity of fecal microbiota transfer in combination with standard of care immunotherapy in advanced hepatocellular carcinoma (HCC) in a parallel group design.
Subjects will be randomized 2:1 into either the FMT or placebo group.